Evotec expands global discovery, development ops with $300M Aptuit buyout
Germany’s Evotec is beefing up its contract drug development organization, buying out rival Aptuit in a deal that will add hundreds of scientists to its organization along with facilities in Basel, Oxford and Verona, Italy. Evotec is paying $300 million in cash for the company and its roster of hundreds of biopharma clients that have looked to Aptuit for everything from discovery through clinical services and into manufacturing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.